TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03448263

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balanced Force technique
Description: Flex-R files sizes 15-45 taper .02 were used according to the technique on each tooth

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balanced Force technique
Description: Flex-R files sizes 15-45 taper .02 were used according to the technique on each tooth

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balanced Force technique
Description: Flex-R files sizes 15-45 taper .02 were used according to the technique on each tooth

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: WaveOne technique
Description: WaveOne instrument was used to prepare narrow, straight and curved canals, and file (40.08) was used for large canals.~Three in-and-out motions were used with lengths not beyond 3 mm in the three thirds of the canal until reaching the estimated WL.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: WaveOne technique
Description: WaveOne instrument was used to prepare narrow, straight and curved canals, and file (40.08) was used for large canals.~Three in-and-out motions were used with lengths not beyond 3 mm in the three thirds of the canal until reaching the estimated WL.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: WaveOne technique
Description: WaveOne instrument was used to prepare narrow, straight and curved canals, and file (40.08) was used for large canals.~Three in-and-out motions were used with lengths not beyond 3 mm in the three thirds of the canal until reaching the estimated WL.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reciproc technique
Description: Reciproc files were used in wide canals. Three in-and-out motions were used with lengths not beyond 3 mm in the three thirds of the canal until reaching the estimated WL.
Study: NCT00231478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: granisetron
Description: 20 micrograms intravenously (iv) 15 min prior to end of surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: granisetron
Description: 40 micrograms intravenously (iv) 15 min prior to end of surgery
Study: NCT03448263

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reciproc technique
Description: Reciproc files were used in wide canals. Three in-and-out motions were used with lengths not beyond 3 mm in the three thirds of the canal until reaching the estimated WL.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reciproc technique
Description: Reciproc files were used in wide canals. Three in-and-out motions were used with lengths not beyond 3 mm in the three thirds of the canal until reaching the estimated WL.
Study: NCT00182702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03484260

Intervention type: DRUG
Intervention: Testosterone Product
Description: Men used testosterone product following prescription
Study: NCT01492556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Lastet (Etoposide Capsules, 25mg\*40 capsules/box), manufactured by Nippon Kayaku Co., Ltd.
Study: NCT04258735

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Genomic analysis
Description: WES, RNASeq, ctDNA, Exosome
Study: NCT03467945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin/Gliclazide Fixed Combination
Description: Participants received single oral dose of Metformin and Gliclazide fixed combination tablet in treatment period 1, 2, 3 or 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin/Gliclazide Fixed Combination
Description: Participants received single oral dose of Metformin and Gliclazide fixed combination tablet in treatment period 1, 2, 3 or 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin/Gliclazide Fixed Combination
Description: Participants received single oral dose of Metformin and Gliclazide fixed combination tablet in treatment period 1, 2, 3 or 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants received single oral dose of Metformin tablet in treatment period 1, 2, 3 or 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants received single oral dose of Metformin tablet in treatment period 1, 2, 3 or 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants received single oral dose of Metformin tablet in treatment period 1, 2, 3 or 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants received single oral dose of Metformin tablet in treatment period 1, 2, 3 or 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gliclazide
Description: Participants received single oral dose of Gliclazide tablet in treatment period 1, 2, 3 or 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gliclazide
Description: Participants received single oral dose of Gliclazide tablet in treatment period 1, 2, 3 or 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gliclazide
Description: Participants received single oral dose of Gliclazide tablet in treatment period 1, 2, 3 or 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gliclazide
Description: Participants received single oral dose of Gliclazide tablet in treatment period 1, 2, 3 or 4.
Study: NCT04225832

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT Coping Intervention
Description: A cognitive behavior therapy group intervention for HIV-negative Latinx sexual minority men aimed at increasing HIV testing and prevention strategies.
Study: NCT01560130

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shape Up Rhode Island + Online weight loss program
Description: Participants assigned to this arm will receive the standard Shape Up Rhode Island statewide intervention and an Internet-based behavioral weight loss program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shape Up Rhode Island + Online weight loss program + Groups
Description: Participants assigned to this arm will receive the standard Shape Up Rhode Island statewide intervention, an Internet-based behavioral weight loss program, and the option to attend group sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shape Up Rhode Island + Online weight loss + Incentives
Description: Participants assigned to this arm will receive the standard Shape Up Rhode Island statewide intervention, an Internet-based behavioral weight loss program, and monetary incentives for submitting self-monitoring information and for achieving clinically significant weight loss.
Study: NCT03917264

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peri-implantitis debridement
Description: Mechanical cleaning of titanium implants, peri-implantitis debridement.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peri-implantitis debridement
Description: Mechanical cleaning of titanium implants, peri-implantitis debridement.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dental hygiene procedures
Description: Titanium scalers and nylon brushed used for implant cleaning

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dental hygiene procedures
Description: Titanium scalers and nylon brushed used for implant cleaning
Study: NCT03682796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRPH-222
Description: administered by IV, 21-day Cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRPH-222
Description: administered by IV, 21-day Cycle
Study: NCT00776997

Intervention type: DEVICE
Group type: OTHER
Intervention: Magnetic Sphincter Augmentation
Description: The area of the lower esophageal sphincter (LES) is accessed using a standard laparoscopic approach. The tubular esophagus, in the area of the LES, is sized and the appropriately sized sphincter augmentation device is placed circumferentially around the esophagus in the area of the LES. After confirming proper placement, the ends of the device are secured. At this point, the implant procedure is complete, laparoscopic instruments are withdrawn and access points are closed.
Study: NCT04233346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: CP-CML patients will be randomized into 30 mg and 45 mg dose groups at the ratio of 1:1,each group taken orally once daily. Other patients taken 45mg orally once daily.
Study: NCT01912118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol will be titrated via a target controlled infusion to reach a specific target BIS (as specified in treatment arm)
Study: NCT04249739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. Keytruda ™ (pembrolizumab) has recently been approved in the United Stated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. Keytruda ™ (pembrolizumab) has recently been approved in the United Stated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
Study: NCT01706380

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive voice response with personal feedback
Description: Personal feedback is given at the end of each automated telephone follow-up call, and reports back to the patient whether his och her symptom status is better, worse or equal, compared to the previous telephone call.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interactive voice response without personal feedback
Description: Control condition. Identical follow-up but without personal feedback.
Study: NCT03041337

Intervention type: DIAGNOSTIC_TEST
Intervention: stress echocardiography
Description: stress echocardiography will be performed in accordance with the current guidelines on a variable load 45° cycle ergometer with an incremental workload of 25 W every 2 minutes up to the symptom-limited maximal tolerated workload. Echocardiographic measurements will be acquired at baseline, at peak exercise and during recovery of 5 minutes.~The electrocardiogram and blood pressure will be monitored at each workload. Termination criteria and / or positive test criteria for inducible myocardial ischemia will follow the current recommendations

Intervention type: DIAGNOSTIC_TEST
Intervention: stress echocardiography
Description: stress echocardiography will be performed in accordance with the current guidelines on a variable load 45° cycle ergometer with an incremental workload of 25 W every 2 minutes up to the symptom-limited maximal tolerated workload. Echocardiographic measurements will be acquired at baseline, at peak exercise and during recovery of 5 minutes.~The electrocardiogram and blood pressure will be monitored at each workload. Termination criteria and / or positive test criteria for inducible myocardial ischemia will follow the current recommendations
Study: NCT00933166

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotrafilcon A contact lens
Description: Investigational silicone hydrogel, single vision, soft contact lens worn on a daily wear basis, flexible wear basis, or extended wear basis for three months
Study: NCT01932463

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate Transcranial System
Description: MR Guided Focused Ultrasound
Study: NCT03362957

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Geniculate Artery Embolization
Description: Gel-Bead Microspheres will be used for geniculate artery embolization (GAE) in subjects with knee osteoarthritis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Geniculate Artery Embolization
Description: Gel-Bead Microspheres will be used for geniculate artery embolization (GAE) in subjects with knee osteoarthritis.

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: Patients will receive a sham procedure, which will include a diagnostic angiogram
Study: NCT00560638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: loteprednol etabonate ophthalmic suspension, 0.5%
Description: TID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: loteprednol etabonate ophthalmic suspension, 0.5%
Description: QID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle of loteprednol etabonate
Description: TID or BID according to the randomization
Study: NCT04308694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacy-based methadone administration and dispensing
Description: Eligible participants receiving between 6- and 13-days of methadone take-home doses will have methadone administration and dispensing transferred from the opioid treatment program to the partnered community pharmacy. Each participant will be assessed monthly for 3 months (at 1, 2, and 3 months following intake/baseline) to explore the feasibility of transferring their methadone administration and dispensing to the select community pharmacy.
Study: NCT02553070

Intervention type: OTHER
Intervention: Survey
Description: Pharmacy students will be asked to participate in a short (5-7 minutes) survey (see below) that contains 21-short cases involving an exposure to a pharmaceutical or non-pharmaceutical agent. All cases involve children less than 19 years of age. Participants will be asked to indicate their year in pharmacy school (1st or 2nd) and their gender (female/male).
Study: NCT01828684

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Therapeutic Lens Coating
Description: Subjects will wear a therapeutic lens coating for 2 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Lens Coating
Description: Subjects will wear a therapeutic lens coating for 2 weeks.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Lens Coating
Description: Each subject will wear a sham lens coating for 2 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Lens Coating
Description: Each subject will wear a sham lens coating for 2 weeks.
Study: NCT00888849

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Advant 55 Linear Cutter/Stapler
Description: Advant 55 Linear Cutter/Stapler

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suturing
Description: Suturing
Study: NCT01527981

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for adherence and depression
Description: Cognitive-behavioral therapy for adherence and depression (CBT-AD) is a weekly, psychosocial treatment focusing on depression and patients' adherence to diabetes self-care. Treatment consists of weekly one-hour sessions for approximately 10 sessions.
Study: NCT03729479

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DASH diet
Description: Participants will be taught to follow a DASH diet (low-sodium and low-fat meal plan, which includes whole grains, fat-free or low-fat dairy products, vegetables, fruits, poultry, fish, and nuts, with processed, high-sodium, regular-fat, and sugar-added foods restricted).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DASH diet
Description: Participants will be taught to follow a DASH diet (low-sodium and low-fat meal plan, which includes whole grains, fat-free or low-fat dairy products, vegetables, fruits, poultry, fish, and nuts, with processed, high-sodium, regular-fat, and sugar-added foods restricted).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Very low carbohydrate, ketogenic diet
Description: Participants will be taught to follow a very low-carbohydrate diet (non-starchy vegetables, nuts, seeds, meat, fish, and natural fats such as avocado, olive oil, and butter, with starchy and sugary foods restricted).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Very low carbohydrate, ketogenic diet
Description: Participants will be taught to follow a very low-carbohydrate diet (non-starchy vegetables, nuts, seeds, meat, fish, and natural fats such as avocado, olive oil, and butter, with starchy and sugary foods restricted).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extras
Description: Participants will be given training in positive affect, mindfulness, health information seeking and sharing, and cooking practices and behavior.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extras
Description: Participants will be given training in positive affect, mindfulness, health information seeking and sharing, and cooking practices and behavior.
Study: NCT04607447

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low intracranial pressure strategy treatment
Description: 1. Supine position for 16h-18h daily, with head toward the affected side in most of the time, and 15-20 cm elevation of lower limbs.~2. Abdominal belt compression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin plus Dexamethasone
Description: Atorvastatin plus Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin plus Dexamethasone
Description: Atorvastatin plus Dexamethasone
Study: NCT01837888

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WheelSee Training Program
Description: WheelSee sessions will be administered by a peer-trainer, who will be trained in a 2-day workshop to use social cognitive approaches (i.e. facilitating successful performance of wheelchair skills, learning through observation of peers, positive verbal reinforcement from peers and family members, and re-interpretation of physiological symptoms) to foster the improvement of self-efficacy for wheelchair use. Each WheelSee session will be tailored to the individual goals of participants, which will be identified during the start of each WheelSee session.
Study: NCT03661580

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural Activation
Description: The BA intervention will be the outpatient version of the Life Enhancement Treatment for Substance Use (LETS ACT; Daughters et al., 2008). This brief, manualised BA intervention has been specifically developed to meet the needs of patients with comorbid substance misuse and depression in drugs and alcohol treatment settings. LETS ACT targets the link between mood, substance use and behaviour, and focuses on identifying and increasing rewarding, substance-free activities that are based on the patient's own personal values.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: The control intervention in this study is Treatment as Usual at the CDAT service. Treatment as Usual consists of planned key-working sessions every 2-4 weeks with an allocated caseworker plus monthly prescribing review appointments with a medical practitioner for patients who require drug treatment medication. Key-working sessions are primarily focused on addressing substance misuse issues using a range of intervention techniques such as motivational interviewing and brief solution-focused therapy.
Study: NCT00663143

Intervention type: PROCEDURE
Intervention: Stromal Cells Sample
Description: Human Bone Marrow Stromal Cells will be obtained from 5 patients. Stromal cells will be obtained from subjects undergoing bone graft procedure to repair traumatic mandible fractures. Bone graft specimens will be obtained from the ileac crest. This will allow easy access to bone marrow specimen without additional pain or complications. A total of 5 ml of bone marrow will be obtained from each patient.
Study: NCT04259489

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shared Care diabetes management
Description: After the inclusion visit, the patients will be randomized to Shared Care group or traditional therapy group. Compared to conventional diabetes education in the traditional therapy group, the Shared Care group provides patients with online services and continuous diabetes management and education through a mobile application. It also addresses that it is important for patients to meet regularly with diabetes multidisciplinary team for better results. The total observation period is 3 years for each patient. The visits will be done every 3 months.
Study: NCT01851369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC102
Description: Methoxyamine hydrochloride (TRC102) has been shown to potentiate the activity of temozolomide by preventing base excision repair (BER) and allowing cleavage of TRC102 bound deoxyribonucleic acid (DNA), which will cause DNA strand breaks in cancer cells. We hypothesize that oral TRC102 can be safely co-administered with Temozolomide (TMZ) and would potentiate DNA damage caused by TMZ resulting in antitumor responses.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT scan
Description: CT scans will be performed at baseline, and repeat scans will be performed every 2 cycles (every 3 cycles for participants on study more than one year).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lomotil
Description: If diarrhea develops and does not have an identifiable cause other than study drug administration, anti-diarrheal's such as Lomotil (diphenoxylate hydrochloride (HCl) 2.5 mg + atropine sulfate 0.025 mg/tablet) dosed according to package insert or loperamide 4 mg by mouth (po) after the first unformed stool with 2 mg po every 2 hours as long as unformed stools continue (4 mg every 4 hours while asleep). No more than 16 mg of loperamide should be taken in during a 24-hour period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prochlorperazine
Description: If a participant develops nausea/vomiting, an anti-emetic such as prochlorperazine may be given.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Description: If a participant develops nausea/vomiting, an anti-emetic such as metoclopramide may be given.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5-HT3 antagonist
Description: If a participant develops nausea/vomiting, an anti-emetic such as 5-HT3 antagonist may be given.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: If a participant develops nausea/vomiting, an anti-emetic such as aprepitant may be given.